Search
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigational[A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963] … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression
Products: Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 7 ADETDidanosine
go.drugbank.com/drugs/DB00900ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains.
Products: BRISTOL VIDEX TABLETAS DE 150 MG, DE LIBERACION RETARDADA X 125 MGBetibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigational[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia
Modafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalThe exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.
Omega-3-acid ethyl esters
go.drugbank.com/drugs/DB09539ApprovedInvestigationalOmega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849]. … Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower
Mixtures: ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI, ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICIDoxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigational[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285] … Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension.
Categories: Adrenergic alpha-1 Receptor AntagonistsDalteparin
go.drugbank.com/drugs/DB06779ApprovedInvestigationalDalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. … It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000.
Products: FRAGMIN 10000 IE, FRAGMIN 10000 IE FSBenzylpenicilloyl polylysine
go.drugbank.com/drugs/DB00895ApprovedInvestigationalThe quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects. … Benzylpenicilloyl polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy.
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalAnifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. … , which may alter patient responses in the experimental and placebo groups; and patient populations were largely homogenous, which may have increased the odds of success of the trial.
Categories: Type I Interferon Receptor AntagonistIcatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigationalrelief was observed to be 8 hours compared to 36 hours for the placebo treatment. … [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema.
Categories: Bradykinin Receptor Antagonists, Bradykinin B2 Receptor Antagonists